Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2022 | Upcoming agents for the treatment of SCD

Santosh Saraf • 21 Jun 2022
EHA 2022
Non-Malignant Sickle Cell Disease

Santosh Saraf, MD, University of Illinois Hospital, Chicago, IL, highlights some upcoming agents for the treatment of sickle cell disease (SCD), drawing focus on PKR activators and gene therapies, as well as agents that may help improve vascular health. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.

More from Santosh Saraf

0:53
Improving quality of life outcomes for patients with SCD
Santosh Saraf • 8 Dec 2023
0:45
Current landscape of treatment for SCD: an update from ASH 2023
Santosh Saraf • 8 Dec 2023
0:47
The role of antiphospholipid antibodies in SCD
Santosh Saraf • 8 Dec 2023
0:42
The role of von Willebrand factor in SCD: predicting complications
Santosh Saraf • 8 Dec 2023

Related Videos

2:01
The MDT in the new era of gene therapy for hemoglobinopathies
Mattia Algeri • 15 Apr 2024
2:38
Treosulfan vs busulfan conditioning in pediatric patients with non-malignant diseases
Rita Beier • 15 Apr 2024
2:18
A global view of transfusion-dependent thalassemia: standard of care, outcomes, and unmet needs
Ali Taher • 15 Apr 2024
1:24
The future of CAR T-reg cells: organ transplantation & autoimmune disease
Zinaida Good • 9 Apr 2024
The content of VJHemOnc is intended for healthcare professionals